Nidufexor

N/A

Report date: 2026/05/03 20:00:15
NME

Base Information

Drug NameNidufexor
Drug Alias NameLMB-763
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBile acid receptor FXR antagonists
TargetsBile acid receptor FXR
Therapy Area/IndicationsDiabetic NephropathiesMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPuerto Rico +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgBeijing Novartis Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetic NephropathiesMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A